Umbrella Study for Single Patient Treatments in Oncology
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
The purpose of this study is to collect data for assessing the improvement of the overall response rate for the overall cohorts and the proportion of patients accessing precision targeted therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients have advanced and rare cancer with limited treatment options.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Patient-specific treatments
Other interventionTreatment will be decided specifically for the patient based on biomarker test results.
Treatment groups
400 Participants
are divided into 3 treatment groupsGroup A: Group 11 intervention
Group B: Group 21 intervention
Group C: Group 31 intervention
Trial outcomes
Primary outcomes
1
Overall response rate for the overall cohorts and the number of patients accessing precision targeted therapy
Time frame
3 yearsSecondary outcomes
1
Overall survival rate
Time frame
5 years2
Progression-free survival
Time frame
5 years3
Number of participants with adverse events as assessed by CTCAE v5.0
For Groups 1 and 2: Only Grade 3 and above AEs/AESIs and SAEs that are related (possibly, probably or definitely) to the study drug. For Group 3: All SAEs (regardless of causality).
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov